Catalyst Wire Dossier Catalyst Wire Dossier

Azenosertib

azenosertib · Zentalis Pharmaceuticals, Inc.
Drug timelines are a Plus or Pro feature.

6 regulatory and trial events tracked for Azenosertib, covering 2026-03-02 to 2026-04-22. Get the full timeline:

Most recent: Clinical Trial Update: A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression [Phase 3]

See pricing